Core Laboratories CLB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$753K-115% | $5.13M-64.7% | $14.52M+36.1% | $10.67M+15,362% | $69K-99.1% | ||
| $3.76M+2.6% | $3.67M+2.1% | $3.59M-2.1% | $3.67M-1.3% | $3.72M+1.4% | ||
| $5.03M+352% | $1.11M-16.0% | $1.33M+146% | $538K-87.1% | $4.16M— | ||
| $3.72M+162% | -$5.99M-526% | $1.41M+4.1% | $1.35M-25.7% | $1.82M+418% | ||
| $180K— | —— | —— | —— | $34K— | ||
| $241K— | —— | $549K-41.3% | $935K+40.0% | $668K— | ||
| -$5.01M-215% | $4.34M— | —— | —— | $6.61M— | ||
| $3.46M+188% | -$3.91M-441% | -$723K-142% | $1.72M+532% | $272K+107% | ||
| $2.85M— | —— | —— | $3.68M+23.7% | $2.97M+233% | ||
| -$845K— | —— | -$2.48M-65.3% | -$1.5M-344% | $617K+344% | ||
| $1.55M+310% | $378K— | $0-100% | $2.21M+259% | -$1.39M-206% | ||
| -$1.93M+71.8% | -$6.86M-667% | $1.21M-26.2% | $1.64M+256% | -$1.05M— | ||
| $730K— | —— | -$286K— | —— | -$872K-168% | ||
| -$844K+50.5% | -$1.71M+8.1% | -$1.86M-182% | -$658K-250% | $440K-79.3% | ||
| $47K— | —— | —— | —— | $45K+645% | ||
| $3.97M-50.1% | $7.95M-6.5% | $8.5M-38.9% | $13.92M+109% | $6.66M-67.7% | ||
| $3.45M+17.1% | $2.94M+46.8% | $2.01M-42.3% | $3.47M+24.7% | $2.79M-14.1% | ||
| $1.49M+123% | $668K+339% | $152K-84.3% | $966K-21.5% | $1.23M+53.4% | ||
| -$3.39M+9.6% | -$3.75M-257% | $2.39M+246% | -$1.64M-313% | $772K+122% | ||
| $460K-1.3% | $466K+0.2% | $465K-0.9% | $469K0.0% | $469K0.0% | ||
| $4M+50.5% | $2.66M-47.0% | $5.01M+82.9% | $2.74M+35.5% | $2.02M-58.8% | ||
| $66M+450% | $12M+9.1% | $11M-8.3% | $12M-7.7% | $13M+117% | ||
| $62M+288% | $16M-20.0% | $20M+66.7% | $12M-20.0% | $15M-25.0% | ||
| $0— | $0+100% | -$274K-2,840% | $10K+11.1% | $9K-52.6% | ||
| -$457K+93.6% | -$7.12M+56.7% | -$16.45M-415% | -$3.2M+28.6% | -$4.48M+76.9% | ||
| $117K— | —— | —— | $9.08M+208% | $2.95M— | ||
| $2.88M+76.4% | $1.63M-34.5% | $2.49M+37.8% | $1.81M-20.1% | $2.26M+6.7% | ||
| $2.97M-67.7% | $9.2M+97.4% | $4.66M+20.8% | $3.86M+280% | $1.02M-82.2% | ||
| $180K— | —— | —— | —— | $34K— | ||
| $3.72M+162% | -$5.99M-526% | $1.41M+4.1% | $1.35M-25.7% | $1.82M+418% | ||
| -$513K-697% | $86K-91.5% | $1.02M-36.9% | $1.61M+307% | -$779K— | ||
| $7K+102% | -$379K-257% | $242K+116% | $112K+3,833% | -$3K-104% | ||
| $1.55M+310% | $378K— | $0-100% | $2.21M+259% | -$1.39M-206% | ||
| $168K— | $0-100% | $809K-17.2% | $977K+51.9% | $643K-66.5% | ||
| —— | $854K0.0% | $854K0.0% | $854K0.0% | $854K+184% | ||
| $730K— | —— | -$286K— | —— | -$872K-168% | ||
| $241K— | —— | $549K-41.3% | $935K+40.0% | $668K— | ||
| $1.44M+104% | $708K-30.9% | $1.02M+19.9% | $854K+7.6% | $794K-30.4% | ||
| -$9K-106% | $148K+7,300% | $2K— | $0— | $0+100% | ||
| $0— | $0-100% | $5.27M+239% | $1.56M-50.1% | $3.12M— | ||
| $1.49M+123% | $668K+339% | $152K-84.3% | $966K-21.5% | $1.23M+53.4% | ||
| $0— | $0+100% | -$274K-2,840% | $10K+11.1% | $9K-52.6% | ||
| —— | $1.02M0.0% | $1.02M0.0% | $1.02M0.0% | $1.02M— | ||
| $1.48M+233% | $445K+138% | $187K— | —— | $1.99M+2,419% | ||
| -$844K+50.5% | -$1.71M+8.1% | -$1.86M-182% | -$658K-250% | $440K-79.3% | ||
| —— | $765.25K0.0% | $765.25K0.0% | $765.25K0.0% | $765.25K— | ||
| $517K-89.7% | $5M-23.0% | $6.5M-37.8% | $10.45M+170% | $3.88M-77.7% | ||
| $517K-89.7% | $5M-23.0% | $6.5M-37.8% | $10.45M+170% | $3.88M-77.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Core Laboratories generate?
- Core Laboratories (CLB) generated $34.3M in operating cash flow over the trailing twelve months.
- What is Core Laboratories's free cash flow?
- After $11.9M of capital expenditures, Core Laboratories's free cash flow was $22.5M over the trailing twelve months, down 51.1% year over year.
- Where does Core Laboratories's cash flow data come from?
- Every line is extracted from Core Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
